Related references
Note: Only part of the references are listed.Advancement in integrin facilitated drug delivery
Daniela Arosio et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
RISC assembly: Coordination between small RNAs and Argonaute proteins
Hotaka Kobayashi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2016)
Precise and efficient siRNA design: a key point in competent gene silencing
E. Fakhr et al.
CANCER GENE THERAPY (2016)
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Amy M. Wen et al.
CHEMICAL SOCIETY REVIEWS (2016)
Molecular mechanisms for vascular complications of targeted cancer therapies
Srila Gopal et al.
CLINICAL SCIENCE (2016)
Nanoparticle-siRNA: A potential cancer therapy?
Samuel Wang Sherng Young et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer
Xiangyu Zhang et al.
DRUG DELIVERY (2016)
ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer
Laura A. Baker et al.
ENDOCRINE-RELATED CANCER (2016)
Androgen receptor signaling pathways as a target for breast cancer treatment
Elisabetta Pietri et al.
ENDOCRINE-RELATED CANCER (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Argonaute: The executor of small RNA function
Azali Azlan et al.
JOURNAL OF GENETICS AND GENOMICS (2016)
Novel agents in the treatment of multiple myeloma: a review about the future
Leonard Naymagon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Dynamic Contrast Enhanced MRI Assessing the Antiangiogenic Effect of Silencing HIF-1α with Targeted Multifunctional ECO/siRNA Nanoparticles
Anthony S. Malamas et al.
MOLECULAR PHARMACEUTICS (2016)
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
Anita K. Bakrania et al.
PHARMACOLOGICAL RESEARCH (2016)
Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy
Yuval Ramot et al.
TOXICOLOGIC PATHOLOGY (2016)
Biomarkers in pancreatic adenocarcinoma: current perspectives
Douglas S. Swords et al.
ONCOTARGETS AND THERAPY (2016)
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm et al.
NATURE REVIEWS MATERIALS (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Substrate engagement of integrins α5β1 and αvβ3 is necessary, but not sufficient, for high directional persistence in migration on fibronectin
Dimitris Missirlis et al.
SCIENTIFIC REPORTS (2016)
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
Paula Garcia-Teijido et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2016)
Triple-Punch Strategy for Triple Negative Breast Cancer Therapy with Minimized Drug Dosage and Improved Antitumor Efficacy
Shishuai Su et al.
ACS NANO (2015)
Transcription factors and chromatin proteins as therapeutic targets in cancer
Simon J. Johnston et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer
Xiao Zhao et al.
BIOMATERIALS (2015)
Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer
Daniel G. Stover et al.
BREAST (2015)
Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer
Jenny G. Parvani et al.
CANCER RESEARCH (2015)
Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics
Sophie Marchal et al.
DRUGS (2015)
The state-of-play and future of platinum drugs
Michael G. Apps et al.
ENDOCRINE-RELATED CANCER (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics
Cornelia Lorenzer et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer
Jia-Yu Liu et al.
MOLECULAR THERAPY (2015)
Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment
Xiaoqi Liu
TRANSLATIONAL ONCOLOGY (2015)
The distribution and degradation of radiolabeled superparamagnetic iron oxide nanoparticles and quantum dots in mice
Denise Bargheer et al.
Beilstein Journal of Nanotechnology (2015)
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Talia Golan et al.
ONCOTARGET (2015)
RNA-Based TWIST1 Inhibition via Dendrimer Complex to Reduce Breast Cancer Cell Metastasis
James Finlay et al.
BIOMED RESEARCH INTERNATIONAL (2015)
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
E. Jokinen et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
Brian M. Necela et al.
PLOS ONE (2015)
The fate of chemoresistance in triple negative breast cancer (TNBC)
Elma A. O'Reilly et al.
BBA CLINICAL (2015)
Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy
Betsy T. Kren et al.
BREAST CANCER RESEARCH (2015)
Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
Lee J. McGhan et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles
Qiang Feng et al.
BIOMATERIALS (2014)
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
Aleix Prat et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors
Beate Schultheis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles
Yang Liu et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin
David Fajardo-Ortiz et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
Jonathan E. Zuckerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Basal-Like and Triple-Negative Breast Cancers Searching for Positives Among Many Negatives
Prasanna Alluri et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
The cell-type specific uptake of polymer-coated or micelle-embedded QDs and SPIOs does not provoke an acute pro-inflammatory response in the liver
Markus Heine et al.
BEILSTEIN JOURNAL OF NANOTECHNOLOGY (2014)
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Elisavet Paplomata et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment
Zhou J. Deng et al.
ACS NANO (2013)
Role of integrated cancer nanomedicine in overcoming drug resistance
Arun K. Iyer et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Targeted Therapy for Breast Cancer
Ali Mohamed et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]
Stephan Seitz et al.
ANTI-CANCER DRUGS (2013)
The relevance of the TGF-β Paradox to EMT-MET programs
Chevaun D. Morrison et al.
CANCER LETTERS (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells
Elizabeth M. H. Kim et al.
JOURNAL OF SURGICAL RESEARCH (2013)
Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β
Jenny G. Parvani et al.
MOLECULAR BIOLOGY OF THE CELL (2013)
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
P. Sivaramakrishna Rachakonda et al.
PLOS ONE (2013)
Mutant KRAS is a druggable target for pancreatic cancer
Elina Zorde Khvalevsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero et al.
CANCER DISCOVERY (2013)
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
Juan Lao et al.
JOURNAL OF DRUG DELIVERY (2013)
Organic nanocarriers for cancer drug delivery
Victor Lopez-Davila et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers
Claudia Scholz et al.
JOURNAL OF CONTROLLED RELEASE (2012)
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Dai Horiuchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Swen Hoelder et al.
MOLECULAR ONCOLOGY (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
Expression and clinical significance of androgen receptor in triple negative breast cancer
Xiang Luo et al.
Chinese Journal of Cancer (2012)
Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers
S. Park et al.
ANNALS OF ONCOLOGY (2011)
Biologically Optimized Nanosized Molecules and Particles: More than Just Size
Michelle R. Longmire et al.
BIOCONJUGATE CHEMISTRY (2011)
Comparative Biodistribution of PAMAM Dendrimers and HPMA Copolymers in Ovarian-Tumor-Bearing Mice
S. Sadekar et al.
BIOMACROMOLECULES (2011)
The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells
Nuo Cao et al.
BIOMATERIALS (2011)
Secondary mutations of BRCA1/2 and drug resistance
Kiranjit K. Dhillon et al.
CANCER SCIENCE (2011)
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2011)
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Rong Hu et al.
CLINICAL CANCER RESEARCH (2011)
Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays
Sophie Giusiano et al.
EUROPEAN JOURNAL OF CANCER (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Daniel J. Toft et al.
MOLECULAR ENDOCRINOLOGY (2011)
Nanoparticle PEGylation for imaging and therapy
Jesse V. Jokerst et al.
NANOMEDICINE (2011)
Self-Assembled and Nanostructured siRNA Delivery Systems
Ji Hoon Jeong et al.
PHARMACEUTICAL RESEARCH (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy
Hiroshi Yagata et al.
BREAST CANCER (2011)
New Nanosized Biocompatible MR Contrast Agents Based on Lysine-Dendri-Graft Macromolecules
Mikako Ogawa et al.
BIOCONJUGATE CHEMISTRY (2010)
Expression of tenascin-C and its isoforms in the breast
David S. Guttery et al.
CANCER AND METASTASIS REVIEWS (2010)
Nanoparticle-Based Delivery System for Application of siRNA In Vivo
Yan Wang et al.
CURRENT DRUG METABOLISM (2010)
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
K. David Voduc et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-beta in Normal and Malignant Mammary Epithelial Cells
Molly A. Taylor et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2010)
Contribution of biomarkers to personalized medicine
Daniel F. Hayes
BREAST CANCER RESEARCH (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
Cara K. Fraser et al.
EXPERIMENTAL HEMATOLOGY (2009)
Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity
Arkadi Zintchenko et al.
BIOCONJUGATE CHEMISTRY (2008)
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
Wim H. De Jong et al.
BIOMATERIALS (2008)
Dasatinib suppresses in vitro natural killer cell cytotoxicity
Stephen J. Blake et al.
BLOOD (2008)
Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Manuela Aleku et al.
CANCER RESEARCH (2008)
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group
Marianne Kyndi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers
Jongdoo Lim et al.
MOLECULAR PHARMACEUTICS (2008)
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Frank Alexis et al.
MOLECULAR PHARMACEUTICS (2008)
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats
Michelle Longmire et al.
NANOMEDICINE (2008)
Modelling Myc inhibition as a cancer therapy
Laura Soucek et al.
NATURE (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Shape effects of filaments versus spherical particles in flow and drug delivery
Yan Geng et al.
NATURE NANOTECHNOLOGY (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Lipid-based nanoparticles for nucleic acid delivery
Weijun Li et al.
PHARMACEUTICAL RESEARCH (2007)
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
A. Santel et al.
GENE THERAPY (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
HER2 therapy - Molecular mechanisms of trastuzumab resistance
Rita Nahta et al.
BREAST CANCER RESEARCH (2006)
beta(3) Integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells
Amy J. Galliher et al.
BREAST CANCER RESEARCH (2006)
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells:: Justification for K-ras-directed therapy
JB Fleming et al.
MOLECULAR CANCER RESEARCH (2005)
Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals
R Guan et al.
CANCER RESEARCH (2005)
Polo-like kinases (Plks) and cancer
N Takai et al.
ONCOGENE (2005)
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1
B Spänkuch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
One-thousand-and-one substrates of protein kinase CK2?
F Meggio et al.
FASEB JOURNAL (2003)
Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer
H Kobayashi et al.
BIOCONJUGATE CHEMISTRY (2001)
Share Paper
